Low Total Testosterone Linked to Chronic Disease
By LabMedica International staff writers Posted on 01 May 2018 |
Image: A liquid chromatography-tandem mass spectrometer (LC-MS/MS) (Photo courtesy of University of Michigan).
A male's total testosterone level may be linked to more than just sexual health and muscle mass preservation. Low amounts of the hormone could also be associated with chronic disease, even among men 40 years of age and younger.
The prevalence of total testosterone (TT) deficiency in men increases with age, and is associated with several deleterious effects to the musculoskeletal system including osteopenia and sarcopenia, as well as with higher rates of all-cause mortality.
Scientists from University of Michigan (Ann Arbor, MI, USA) evaluated the association between total testosterone (TT) deficiency and weakness on multimorbidity in men. Analyses were performed to examine the prevalence of multimorbidity among 2,399 young, middle-aged, and older men, with and without testosterone deficiency. Fasting and non-fasting measures of HDL-cholesterol, triglycerides, and glucose were measured. Non-fasting serum measures of glycated hemoglobin (HbA1c) were included as a diagnostic test for untreated diabetes, which reflects average plasma glucose for the previous ~three-months. TT levels were measured in serum using isotope dilution liquid chromatography tandem mass spectrometry.
The investigators found that multimorbidity was more prevalent among men with testosterone deficiency, compared to normal TT in the entire group (36.6% versus 55.2%). However, differences were only seen within young (testosterone deficiency: 36.4%; normal TT: 13.5%; and older men (testosterone deficiency: 75.0%; normal TT: 61.5%). Low TT and weakness in men were independently associated with multimorbidity at all ages; however, multimorbidity was more prevalent among young and older men with testosterone deficiency. Prevalence of testosterone deficiency was 30.8% for the entire sample, and 22.6%, 35.8%, and 34.6% for young, middle-aged, and older men, respectively.
Mark Peterson, PhD, MS, FACSM, an assistant professor and lead author of the study, said, “We found a large dose-response relationship between the age-specific low total testosterone and moderate total testosterone levels and multimorbidity, even after adjusting for obesity and muscle strength capacity. This means that men should be concerned about declining total testosterone, even if it has not reached a level to warrant a clinical diagnosis of less than 300 ng/dL (10.4 nmol/L).” The study was published on April 12, 2018, in the Journal Scientific Reports.
Related Links:
University of Michigan
The prevalence of total testosterone (TT) deficiency in men increases with age, and is associated with several deleterious effects to the musculoskeletal system including osteopenia and sarcopenia, as well as with higher rates of all-cause mortality.
Scientists from University of Michigan (Ann Arbor, MI, USA) evaluated the association between total testosterone (TT) deficiency and weakness on multimorbidity in men. Analyses were performed to examine the prevalence of multimorbidity among 2,399 young, middle-aged, and older men, with and without testosterone deficiency. Fasting and non-fasting measures of HDL-cholesterol, triglycerides, and glucose were measured. Non-fasting serum measures of glycated hemoglobin (HbA1c) were included as a diagnostic test for untreated diabetes, which reflects average plasma glucose for the previous ~three-months. TT levels were measured in serum using isotope dilution liquid chromatography tandem mass spectrometry.
The investigators found that multimorbidity was more prevalent among men with testosterone deficiency, compared to normal TT in the entire group (36.6% versus 55.2%). However, differences were only seen within young (testosterone deficiency: 36.4%; normal TT: 13.5%; and older men (testosterone deficiency: 75.0%; normal TT: 61.5%). Low TT and weakness in men were independently associated with multimorbidity at all ages; however, multimorbidity was more prevalent among young and older men with testosterone deficiency. Prevalence of testosterone deficiency was 30.8% for the entire sample, and 22.6%, 35.8%, and 34.6% for young, middle-aged, and older men, respectively.
Mark Peterson, PhD, MS, FACSM, an assistant professor and lead author of the study, said, “We found a large dose-response relationship between the age-specific low total testosterone and moderate total testosterone levels and multimorbidity, even after adjusting for obesity and muscle strength capacity. This means that men should be concerned about declining total testosterone, even if it has not reached a level to warrant a clinical diagnosis of less than 300 ng/dL (10.4 nmol/L).” The study was published on April 12, 2018, in the Journal Scientific Reports.
Related Links:
University of Michigan
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines